The Incremental Value of Diuretic Dose in Staging Systems for Transthyretin Cardiac Amyloid: Keep It Simple

Affiliations

Editorial

Martha Grogan. JACC CardioOncol. 2020.

. 2020 Sep 15;2(3):425-427.

doi: 10.1016/j.jaccao.2020.07.004. eCollection 2020 Sep.

¹ Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.

No abstract available

Keywords: cardiac amyloidosis; heart failure; transthyretin.

Figures

Diuretic Dose and NYHA Functional Class Are Independent Predictors of Mortality in Patients With Transthyretin Cardiac Amyloidosis.
Cheng RK, Levy WC, Vasbinder A, Teruya S, De Los Santos J, Leedy D, Maurer MS. Cheng RK, et al. JACC CardioOncol. 2020 Sep;2(3):414-424. doi: 10.1016/j.jaccao.2020.06.007. Epub 2020 Sep 15. JACC CardioOncol. 2020. PMID: 33073249 Free PMC article.

1. Ruberg F.L., Grogan M., Hanna M., Kelly J.W., Maurer M.S. Transthyretin amyloid cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73:2872–2891. - PMC - PubMed
1. Gillmore J.D., Maurer M.S., Falk R.H. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133:2404–2412. - PubMed
1. Maurer M.S., Schwartz J.H., Gundapaneni B. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007–1016. - PubMed
1. Grogan M., Scott C.G., Kyle R.A. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68:1014–1020. - PubMed
1. Gillmore J.D., Damy T., Fontana M. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39:2799–2806. - PubMed